The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Slow going but up 10% now. It looks like most of the buys are being held back by the MM's and will be reported late.
£1.495 to buy now so this could go much higher if the buys start piling in.
Yes, there is an advantage for pumps , but in many ways I think the first advantage will be for the type 2 who self inject.
Reducing the volume of injection required by 5 will make it more convenient and less painful.
I know that Arecor's technology typically enables storage at room temperatures - if that's also the case with AT278 then that's another big advantage, in terms of convenience and pain.
Hi Art, If you look at my post of 27th Feb...I think you will find the reason for lack of performance....In my opinion Arecor is trading at completely the wrong level, but unfortunately until the seller is out of the way I don't think it can get to the levels it justifies. This is a great opportunity.
I hate it when this happens - great RNS, share price at an all-time low, cash-healthy (that is an assumption without looking into all the details but considering there were 27,683,532 shares in issue on admission in June 2021 and there are only 30,642,000 shares in issue now 3 years later there certainly hasn't been much dilution so whatever is keeping them funded it is not continual placings) and the share price just sits there with virtually no trades at all.
It's massive positive news.
"Creates potential to be the first, and only, ultra-concentrated (500 U/mL) ultra-rapid insulin product enabling miniaturisation of next-generation insulin pumps."
"The insulin pump market is valued at circa $5.5bn market today, with a significant opportunity for substantial growth in this market by expanding use across the Type 1 and Type 2 patient population that can be further enabled by AT278 and a next-generation insulin pump."
This huge news is just about completely unnoticed so far.
This looks like a very positive RNS to me even though I am not familiar with this share and I certainly bought some on opening. Presentation tomorrow. This appears to be unloved and unnoticed and there isn't much action here as yet though I reckon that might pick up later.
ATB
They are talking about an oral version of Wegovy/Ozempic, which could be huge if they can improve upon the bioavailability of extant formulations.
I think I know the reason for the current weakness in the share price. Downing LLP are closing down and as such liquidating their positions. The last I saw was that they held just over 5% of Arecor, but that was from over a year ago and they have been selling for some time now. I do not know how many they have left, but I believe this is an opportunity to either add or take a position in the company at, in my opinion, bargain basement prices. I do not believe the share would be at current levels but for this special situation.
I bought 9,000 @ 166.88 just after opening, not showing ...
I have no idea why, but there must be a large seller. All the volume in recent days have been buys...I bought some this morning, but the price is not moving. Time was that it was v illiquid, but I think at least 25k has been bought over the week and the price has not moved.
Sanofi to acquire INBRX-101 for up to $2.2 billion.
hxxps://www.prnewswire.com/news-releases/inhibrx-announces-sale-of-inbrx-101-to-sanofi-for-an-aggregate-value-of-up-to-2-2b-302041424.html
News or no News, named partners or not, this share price is not for moving.... I guess the company will have to show good figures in its financials before the world wakes up, responds etc.
The diabetes treatment grabs all of the headlines but there is a lot more to the company than just this.
Sounds very interesting, will it attract a takeover bid?
Market has again failed to react to good news from the company. Hopefully they will get further exposure at the diabetes conference in the US. If the market continues to ignore this company surely it must become a potential takeover target?
Our highly innovative formulation technology addresses these challenges and, when applied, we are able to develop enhanced novel pharmaceutical products, both for our growing partnerships with Pharma companies and in our proprietary pipeline. This US patent is a very important addition to our IP portfolio, protecting a formulation design space that enables monoclonal antibodies with superior stability.
Sounds good to me!
:-)
In case you missed our webinar with Arecor Therapeutics plc (AREC) earlier this month, the recording can be found on our YouTube channel: https://youtu.be/UjdNjbBBWdw
Sanofi hones in on type 1 diabetes in $2.9 bln Provention Bio deal
https://www.reuters.com/markets/deals/frances-sanofi-acquire-us-based-provention-bio-29-bln-2023-03-13/
https://www.thisismoney.co.uk/money/investing/article-11847771/MIDAS-SHARE-TIPS-dose-profits-diabetes-jabs-Arecor.html?ico=mol_desktop_money-newtab&molReferrerUrl=https%3A%2F%2Fwww.dailymail.co.uk%2Fmoney%2Findex.html&_ga=2.81489175.1643311655.1678573927-1843241439.1674940599&_gl=1*gp4448*_ga*MTg0MzI0MTQzOS4xNjc0OTQwNTk5*_ga_XE0XLFFF16*MTY3ODU3MzkyNi41LjEuMTY3ODU3Mzk2MS4wLjAuMA..
I missed it. What were the key takeaways?